Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma

Johannes M Waldschmidt; Noori Sotudeh; Sankalp Arora; Tushara Vijaykumar; Praveen Anand; Hannah Stuart; Julia Frede; Timothy B Campbell; Shari Kaiser; Xirong Zheng; Nikhil C Munshi; Kenneth C Anderson; Hermann Einsele; Andrew J Yee; Birgit Knoechel; Jens G Lohr; Noopur S Raje

doi:10.1182/bloodadvances.2024015285

Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma

Blood Adv. 2025 Jan 15:bloodadvances.2024015285. doi: 10.1182/bloodadvances.2024015285. Online ahead of print.

Authors

Johannes M Waldschmidt¹, Noori Sotudeh¹, Sankalp Arora², Tushara Vijaykumar¹, Praveen Anand¹, Hannah Stuart¹, Julia Frede¹, Timothy B Campbell³, Shari Kaiser⁴, Xirong Zheng⁵, Nikhil C Munshi⁶, Kenneth C Anderson¹, Hermann Einsele⁷, Andrew J Yee⁸, Birgit Knoechel⁹, Jens G Lohr¹, Noopur S Raje⁹

Affiliations

¹ Dana-Farber Cancer Institute, Boston, Massachusetts, United States.
² Massachussetts General Hospital, United States.
³ Bristol-Myers Squibb, Brisbane, California, United States.
⁴ Bristol Myers Squibb, Seattle, Washington, United States.
⁵ Bristol Myers Squibb, Princeton, New Jersey, United States.
⁶ Dana Farber Cancer Institute, Boston, Massachusetts, United States.
⁷ Universitätsklinikum Würzburg, Würzburg, Germany.
⁸ Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States.
⁹ Harvard Medical School, United States.

PMID: 39813623
DOI: 10.1182/bloodadvances.2024015285

Abstract

Efficacy and durability remain central shortcomings of T-cell based therapies in multiple myeloma (MM). Here, we employ blood-based transcriptional T-cell profiling to define impaired T-cell fitness as putative biomarker associated with sensitivity to PD1 inhibition in CAR-T refractory MM patients.